CARCINOMA, NON-SMALL-CELL LUNG

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) and have no signs of cancer left. The goal is to see if the vaccine can train the immune system to recogniz…

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with advanced solid tumors that have HER2 alterations (too much or a different type of HER2 protein). The tumors have spread or cannot be removed by surgery. The main goal is to see if the treatment…

This study tests whether adding the drug durvalumab to precise, high-dose radiation (SBRT) helps keep early-stage lung cancer from coming back in patients who cannot have surgery. About 724 adults with stage I/II non-small cell lung cancer will receive either durvalumab or a plac…

This early-stage study tests a new oral medication, PF-07985045, alone or with other cancer drugs, in people with advanced solid tumors that have a KRAS gene mutation. The cancers studied include non-small cell lung, colorectal, and pancreatic cancers. The main goals are to check…

This trial aimed to test a new treatment for people with metastatic non-small cell lung cancer. Doctors would take immune cells from a patient's tumor, use CRISPR gene editing to make them stronger, and then put them back into the patient. The goal was to see if these edited cell…

This study tests the targeted drug osimertinib (Tagrisso) in 30 people with advanced EGFR-mutant non-small cell lung cancer who have not had prior EGFR inhibitor treatment. The main goal is to understand why the drug stops working by comparing tumor samples taken before and after…

This study looks at whether special skin care can lower the chance of bad rashes and other skin problems in people with advanced lung cancer who are taking two drugs (amivantamab and lazertinib). About 305 patients will be assigned to different skin care routines to see which wor…

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutated non-small cell lung cancer. About 532 adults with stage IIIB, IIIC, or IV lung cancer that cannot be surgically removed are being observ…

This early-stage study tests an experimental drug called SGN-MesoC2 in 19 adults with advanced solid tumors (like lung, ovarian, or pancreatic cancer) that have not responded to standard treatments. The drug is designed to stick to cancer cells and kill them. The main goals are t…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) live longer without the cancer growing. The study includes 776 adults wh…

This study tests whether a combination of two drugs, amivantamab and lazertinib, works better than the standard drug osimertinib for people with advanced non-small cell lung cancer that has certain EGFR gene mutations. About 1,074 participants who have not had prior treatment wil…

This study tests whether adding sacituzumab govitecan to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 614 participants will receive either the c…

This study tested whether the drug durvalumab can help people with stage III lung cancer that cannot be surgically removed. After completing chemotherapy and radiation, 407 participants received either durvalumab or a placebo every few weeks. The goal was to see if durvalumab cou…

This study tests new drug combinations in 43 adults with advanced EGFR-mutant non-small cell lung cancer that has been treated before. The goal is to see if these combinations are safe and can shrink tumors. Participants receive one of several experimental drug pairs, and researc…

This phase 3 study compares an experimental drug, sigvotatug vedotin, to the standard chemo docetaxel in people with advanced non-small cell lung cancer that has spread or can't be removed. About 700 adults who have already tried platinum chemo and an immunotherapy will be random…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before and after surgery can help people with early-stage non-small cell lung cancer live longer without their cancer coming back. About 461 participants with resectable stage II to IIIB lun…

This early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the tre…

This study tests whether adding the drug amivantamab to standard chemotherapy helps people with a specific type of advanced lung cancer (EGFR exon 20 insertion mutation) live longer without their cancer growing. About 308 adults with non-small cell lung cancer that has spread wil…

This study tests a new drug called THIO, which targets telomeres (parts of chromosomes), followed by the immunotherapy cemiplimab in people with advanced non-small cell lung cancer whose cancer stopped responding to initial immunotherapy. The goal is to see if this sequence can s…

This study reviews medical records of 35 adults with ROS1-positive non-small cell lung cancer that had stopped responding to prior treatments. All participants took lorlatinib pills at home until their cancer progressed. Researchers will measure how long the drug controlled the c…

This early-stage study tests a new oral drug, LOXO-260, in about 70 adults whose cancers (like certain lung or thyroid cancers) have a specific RET gene change and have stopped responding to other targeted treatments. The main goals are to find the safest dose and check for side …

This study tests an experimental drug called disitamab vedotin in 120 adults with advanced head/neck, lung, endometrial, or ovarian cancers that have the HER2 marker. The drug is designed to stick to cancer cells and kill them. Participants receive the drug every two weeks to see…

This early-stage study tests a combination of two drugs, amivantamab and docetaxel, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo can shrink tumors. About 12 participants will take part, and the study fo…

This study compares two targeted drugs, lorlatinib and crizotinib, in people with advanced ALK-positive non-small cell lung cancer who have not had prior treatment. The main goal is to see if lorlatinib can delay cancer growth longer than crizotinib. About 296 participants will r…

This study was designed for people with advanced non-small cell lung cancer that could not be removed by surgery. It planned to use a combination of chemotherapy drugs (cisplatin and docetaxel) along with radiation therapy to shrink tumors and control the disease. However, the st…

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has specific gene mutations (S…

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and others that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 98…

This early-stage study tests two experimental drugs, lazertinib and amivantamab, alone or together, in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goals are to find safe doses and see if the combination shrinks tumo…

This study tested a drug called tisotumab vedotin, alone or with other cancer drugs, in 350 people with advanced colorectal, lung, pancreatic, or head and neck cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and to t…

This study tests whether taking alectinib pills for two years after lung cancer surgery works better than standard chemotherapy to prevent the cancer from returning. It includes 257 adults with a specific type of lung cancer called ALK-positive, at stages IB to IIIA. Participants…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells. About 119 participants will receive the drug ever…

This program gives patients with serious non-small cell lung cancer access to the drug capmatinib when no other treatments are available and they cannot join a clinical trial. It is not a study to test the drug, but a way for doctors to request it for individual patients who migh…

This study tests whether giving a different immunotherapy drug (ipilimumab) and targeted radiation can make a standard immunotherapy (anti-PD-1) work again for people with advanced non-small cell lung cancer. About 54 participants will receive this combination to see if it shrink…

This study looks at whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help people with non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if this c…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This study tests a combination of two drugs, amivantamab and capmatinib, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combination can shrink tumors. About 57 adults with specific genetic changes (MET mutation…

This study tests whether the drug selpercatinib can delay the return of non-small cell lung cancer in people with a specific genetic change (RET fusion) after they have had surgery or radiation. About 152 participants will receive either selpercatinib or a placebo for up to three…

This study tests a new drug called JDQ443, given alone or with other treatments, for people with advanced solid tumors that have a specific change in the KRAS gene (G12C). The goal is to find safe doses and see if the drug can shrink tumors. About 74 adults with lung or colorecta…

This study tests a new drug called JDQ443, alone or with other medicines, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 344 adults whose cancer has not responded to standard treatm…

This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the spinal cord. The goal is to see how well the drug shrinks tumors in the brain and controls the disease. About 41 adults will take pa…

This study is for people with advanced non-small cell lung cancer who have already tried other treatments. It tests the safety of adding an experimental drug called MK-3475 to standard chemotherapy with gemcitabine. The goal is to find the best dose and see if the combination hel…

This study tests whether adding a special type of radiation therapy (hypofractionated radiation) to the standard immunotherapy drug durvalumab is safe and effective for people with stage III non-small cell lung cancer. The treatment targets any remaining tumor after initial chemo…

This study tests an experimental pill called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take the pill daily, sometimes with chemotherapy, and continue…

This study tests whether a newer drug, entrectinib, works better than the current standard, crizotinib, in people with advanced ROS1-positive non-small cell lung cancer, including those whose cancer has spread to the brain. About 220 participants will take one of the two pills da…

This study tests whether a newer targeted drug, repotrectinib, works better than the current standard crizotinib for people with advanced ROS1-positive non-small cell lung cancer who have not had prior targeted therapy. About 190 participants will be randomly assigned to one of t…

This study tests a combination of two drugs, amivantamab and cetrelimab, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo shrinks tumors. About 71 participants are enrolled, and the study tracks side effect…

This study tests whether giving dexamethasone, montelukast, or methotrexate before an amivantamab infusion can reduce or prevent infusion-related reactions in people with advanced non-small cell lung cancer. The trial enrolled 68 participants who had previously taken osimertinib.…

This study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer choose wisely about continuing or stopping cancer treatments. The goal is to reduce the use of chemotherapy and other treatments in the last month of …

This study looks at how the immune system changes in people with stage III non-small cell lung cancer during chemoradiation followed by the immunotherapy drug durvalumab. Researchers want to find patterns in immune cells that could predict how well a patient responds to treatment…

This study looks at whether educating doctors in smaller city and county hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted therap…

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IIIC/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments doctors use, ho…

This study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. Researchers analyze these samples to find biological markers that could predict how cancer will behave or respond to treatments. The goal is to impro…